Drug intelligence / Profile preview

KQB368

Development stage: Phase 1
Lead developer: Kumquat Biosciences

Overview

KQB368 is an investigational drug candidate being developed by Kumquat Biosciences. It is designed to target cancers with KRAS mutations, a common oncogenic driver in several solid tumors. The compound is currently in the IND-enabling stage, which means it is undergoing preclinical studies required before initiating human clinical trials. The specific mechanism of action and molecular modality have not been publicly disclosed as of June 2025, but its development focus on KRAS-mutant cancers suggests it may act as a targeted therapy against mutant KRAS or related pathways[1].

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on KQB368.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KQB368.